摘要
目的 :评价哌拉西林钠 /舒巴坦钠 (2∶1)的体内抗菌活性。方法 :用产酶的金黄色葡萄球菌、大肠埃希菌、肺炎克雷伯菌及铜绿假单胞菌建立感染动物模型 ,用哌拉西林钠 /舒巴坦钠 (2∶1)及单用哌拉西林钠、舒巴坦钠及对照药阿莫西林钠 /舒巴坦钠 (2∶1)通过静脉注射、皮下注射进行感染动物的治疗 ,评价对感染小鼠的保护作用。结果 :舒巴坦钠对感染小鼠的抗菌保护作用极弱 ,ED50 均 >40 0mg/kg ,哌拉西林钠静脉注射单用对四种菌感染动物的ED50 分别为 5 5 71mg/kg、 6 5 4mg/kg、 2 4 0 9mg/kg与 11 0 7mg/kg;哌拉西林钠 /舒巴坦钠 (2∶1)者为 2 7 96mg/kg、 2 49mg/kg、 6 75mg/kg与 6 36mg/kg ,分别比哌拉西林钠强 2、 2 5、 3 5与 1 8倍。哌拉西林钠皮下注射单用对四种菌感染动物的ED50 分别为哌拉西林钠 ,哌拉西林钠 /舒巴坦钠 (2∶1)皮下注射对四种产酶菌感染小鼠的保护作用弱于静脉注射者 ,ED50 分别为 5 1 95mg/kg、 4 41mg/kg、 8 19mg/kg与 10 5 8mg/kg,但仍比哌拉西林钠强 1 2、 2、 3 6与 1 5倍。结论 :无论静脉注射或皮下注射 ,哌拉西林钠 /舒巴坦钠 (2∶1)对上述四种产酶菌株感染小鼠的体内抗菌活性 (DE50 )均明显优于哌拉西林钠、舒巴坦钠单用 ,也强于阿莫西林 /舒巴坦钠 (2∶1)。
Objective:To evaluate the antibacterial activities of piperacillin/sulbactam(2∶1)in vivo.Method:Mice infection models were established by using beta-lactamase producing strains S.aureus,E.coli,K.pneumoniae and P.aeruginosa.The trial products including piperacillin,sulbactam,piperacillin/sulbactam(2∶1)and amoxicillin/sulbactam(2∶1)were given intravenously or subcutaneously.Results:Sulbactam,with ED 50 >400mg/kg,provided little protection for infected mice.The ED 50 of piperacillin monotherapy intravenously for S.aureus,E.coli,K.pneumoniae and P.aeruginosa infected mice were 55.71mg/kg,6.54mg/kg,24.09mg/kg and 11.07mg/kg,respectively.That of piperacillin/sulbactam(2∶1)were 27.96mg/kg,2.49mg/kg,6.75mg/kg and 6.36mg/kg,respectively.The protection effects of combination were 2-,2.5-,3.5-and 1.8-fold than monotherapy.The ED 50 of piperacillin monotherapy subcutaneously for the 4 strains infected mice were 60.00mg/kg,9.14mg/kg,29.87mg/kg and 16.71mg/kg,respectively.That of piperacillin/sulbacrtam(2∶1)were 51.95mg/kg,4.41mg/kg,,8.19mg/kg, and 10.58mg/kg,respectively.The protection effects of combination were 1.2-,2-,3.6- and 1.5-fold than monotherapy.Conclusion:piperacillin/ sulbactam(2∶1)was more active than piperacillin monotherapy and amoxicillin/ sulbactam(2∶1)in treating infection models established by beta-lactamase producing strain.Intravenous injection is the optimal route for clinical use.
出处
《华西医学》
CAS
2002年第3期376-377,共2页
West China Medical Journal
